ASND vs. ONC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ASND and ONC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ONC’s market capitalization of 24.39 billion USD is significantly greater than ASND’s 10.52 billion USD, highlighting its more substantial market valuation.
With betas of 0.36 for ASND and 0.29 for ONC, both stocks show similar sensitivity to overall market movements.
ASND and ONC are both American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies without directly engaging with overseas stock exchanges.
| Symbol | ASND | ONC |
|---|---|---|
| Company Name | Ascendis Pharma A/S | BeOne Medicines Ltd. |
| Country | DK | KY |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Pharmaceuticals |
| CEO | Jan Moller Mikkelsen | John V. Oyler |
| Price | 174.18 USD | 245.49 USD |
| Market Cap | 10.52 billion USD | 24.39 billion USD |
| Beta | 0.36 | 0.29 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 28, 2015 | February 2, 2016 |
| ADR | Yes | Yes |
Historical Performance
This chart compares the performance of ASND and ONC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ASND
191.42%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ASND’s Return on Equity of 191.42% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
ONC
-11.51%
Medical - Pharmaceuticals Industry
- Max
- -11.51%
- Q3
- -11.51%
- Median
- -28.40%
- Q1
- -54.57%
- Min
- -54.57%
ONC has a negative Return on Equity of -11.51%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Return on Invested Capital
ASND
-50.64%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ASND has a negative Return on Invested Capital of -50.64%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
ONC
-9.31%
Medical - Pharmaceuticals Industry
- Max
- 3.07%
- Q3
- 0.40%
- Median
- -9.25%
- Q1
- -9.31%
- Min
- -9.31%
ONC has a negative Return on Invested Capital of -9.31%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
Net Profit Margin
ASND
-92.67%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ASND has a negative Net Profit Margin of -92.67%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
ONC
-9.40%
Medical - Pharmaceuticals Industry
- Max
- -3.80%
- Q3
- -5.21%
- Median
- -8.76%
- Q1
- -9.40%
- Min
- -9.40%
ONC has a negative Net Profit Margin of -9.40%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin
ASND
-90.54%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ASND has a negative Operating Profit Margin of -90.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
ONC
-7.08%
Medical - Pharmaceuticals Industry
- Max
- 4.55%
- Q3
- 0.04%
- Median
- -2.01%
- Q1
- -7.08%
- Min
- -7.08%
ONC has a negative Operating Profit Margin of -7.08%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ASND | ONC |
|---|---|---|
| Return on Equity (TTM) | 191.42% | -11.51% |
| Return on Assets (TTM) | -32.19% | -6.72% |
| Return on Invested Capital (TTM) | -50.64% | -9.31% |
| Net Profit Margin (TTM) | -92.67% | -9.40% |
| Operating Profit Margin (TTM) | -90.54% | -7.08% |
| Gross Profit Margin (TTM) | 85.30% | 84.81% |
Financial Strength
Current Ratio
ASND
1.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ASND’s Current Ratio of 1.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
ONC
1.96
Medical - Pharmaceuticals Industry
- Max
- 2.08
- Q3
- 2.08
- Median
- 1.96
- Q1
- 0.82
- Min
- 0.61
ONC’s Current Ratio of 1.96 aligns with the median group of the Medical - Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ASND
-4.46
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
ASND has a Debt-to-Equity Ratio of -4.46, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
ONC
0.28
Medical - Pharmaceuticals Industry
- Max
- 11.35
- Q3
- 6.06
- Median
- 3.76
- Q1
- 2.54
- Min
- 0.28
Falling into the lower quartile for the Medical - Pharmaceuticals industry, ONC’s Debt-to-Equity Ratio of 0.28 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
ASND
-3.72
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ASND has a negative Interest Coverage Ratio of -3.72. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ONC
--
Medical - Pharmaceuticals Industry
- Max
- 1.42
- Q3
- 0.39
- Median
- -3.07
- Q1
- -7.31
- Min
- -10.72
Interest Coverage Ratio data for ONC is currently unavailable.
Financial Strength at a Glance
| Symbol | ASND | ONC |
|---|---|---|
| Current Ratio (TTM) | 1.04 | 1.96 |
| Quick Ratio (TTM) | 0.71 | 1.71 |
| Debt-to-Equity Ratio (TTM) | -4.46 | 0.28 |
| Debt-to-Asset Ratio (TTM) | 0.80 | 0.17 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.34 | 12.96 |
| Interest Coverage Ratio (TTM) | -3.72 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ASND and ONC. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ONC
0.00%
Medical - Pharmaceuticals Industry
- Max
- 11.18%
- Q3
- 4.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ONC
0.00%
Medical - Pharmaceuticals Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ASND | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ASND
-25.98
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ASND has a negative P/E Ratio of -25.98. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
ONC
-66.90
Medical - Pharmaceuticals Industry
- Max
- --
- Q3
- --
- Median
- --
- Q1
- --
- Min
- --
ONC has a negative P/E Ratio of -66.90. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
Forward P/E to Growth Ratio
ASND
-2.36
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ASND has a negative Forward PEG Ratio of -2.36. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
ONC
0.00
Medical - Pharmaceuticals Industry
- Max
- 2.76
- Q3
- 2.07
- Median
- 1.38
- Q1
- 0.69
- Min
- 0.00
In the lower quartile for the Medical - Pharmaceuticals industry, ONC’s Forward PEG Ratio of 0.00 is a positive indicator. It suggests that the stock may be attractively valued relative to its expected earnings growth.
Price-to-Sales Ratio
ASND
24.22
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ASND’s P/S Ratio of 24.22 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ONC
5.84
Medical - Pharmaceuticals Industry
- Max
- 5.74
- Q3
- 5.74
- Median
- 5.66
- Q1
- 2.83
- Min
- 0.07
With a P/S Ratio of 5.84, ONC trades at a valuation that eclipses even the highest in the Medical - Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
ASND
-46.77
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
ONC
7.50
Medical - Pharmaceuticals Industry
- Max
- 130.20
- Q3
- 55.61
- Median
- 10.51
- Q1
- 5.88
- Min
- 1.39
The P/B Ratio is often not a primary valuation metric for the Medical - Pharmaceuticals industry.
Valuation at a Glance
| Symbol | ASND | ONC |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -25.98 | -66.90 |
| Forward PEG Ratio (TTM) | -2.36 | 0.00 |
| Price-to-Sales Ratio (P/S, TTM) | 24.22 | 5.84 |
| Price-to-Book Ratio (P/B, TTM) | -46.77 | 7.50 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -29.03 | -101.44 |
| EV-to-EBITDA (TTM) | -37.74 | -195.01 |
| EV-to-Sales (TTM) | 25.11 | 5.48 |